DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,412 filers reported holding DANAHER CORPORATION in Q3 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $554,753 | -9.5% | 2,398 | -2.9% | 0.06% | -16.9% |
| Q3 2023 | $612,807 | +3.4% | 2,470 | 0.0% | 0.08% | +10.0% |
| Q2 2023 | $592,800 | -5.2% | 2,470 | -0.4% | 0.07% | -12.5% |
| Q1 2023 | $625,311 | -6.5% | 2,481 | -1.5% | 0.08% | -10.1% |
| Q4 2022 | $668,593 | -1.4% | 2,519 | -4.0% | 0.09% | -11.9% |
| Q3 2022 | $678,000 | +2.0% | 2,625 | 0.0% | 0.10% | +9.8% |
| Q2 2022 | $665,000 | -15.4% | 2,625 | -2.0% | 0.09% | 0.0% |
| Q1 2022 | $786,000 | -62.7% | 2,678 | -58.2% | 0.09% | -58.4% |
| Q4 2021 | $2,107,000 | +7.9% | 6,403 | -0.1% | 0.22% | -3.1% |
| Q3 2021 | $1,952,000 | +13.5% | 6,411 | 0.0% | 0.23% | +12.9% |
| Q2 2021 | $1,720,000 | +19.2% | 6,411 | 0.0% | 0.20% | +10.4% |
| Q1 2021 | $1,443,000 | +1.9% | 6,411 | +0.6% | 0.18% | -3.7% |
| Q4 2020 | $1,416,000 | +38.7% | 6,373 | +34.5% | 0.19% | +15.2% |
| Q3 2020 | $1,021,000 | +19.6% | 4,740 | -1.9% | 0.16% | +13.0% |
| Q2 2020 | $854,000 | +27.7% | 4,830 | 0.0% | 0.15% | +7.4% |
| Q1 2020 | $669,000 | -9.7% | 4,830 | 0.0% | 0.14% | +12.4% |
| Q4 2019 | $741,000 | +6.2% | 4,830 | 0.0% | 0.12% | -0.8% |
| Q3 2019 | $698,000 | +1.2% | 4,830 | 0.0% | 0.12% | +1.7% |
| Q2 2019 | $690,000 | +8.2% | 4,830 | 0.0% | 0.12% | +5.3% |
| Q1 2019 | $638,000 | +28.1% | 4,830 | 0.0% | 0.11% | +14.0% |
| Q4 2018 | $498,000 | -5.1% | 4,830 | 0.0% | 0.10% | +12.4% |
| Q3 2018 | $525,000 | +10.1% | 4,830 | 0.0% | 0.09% | +1.1% |
| Q2 2018 | $477,000 | +0.8% | 4,830 | 0.0% | 0.09% | -1.1% |
| Q1 2018 | $473,000 | +5.6% | 4,830 | 0.0% | 0.09% | +7.2% |
| Q4 2017 | $448,000 | +35.8% | 4,830 | +25.5% | 0.08% | +31.7% |
| Q3 2017 | $330,000 | -8.1% | 3,850 | -9.4% | 0.06% | -10.0% |
| Q2 2017 | $359,000 | -5.8% | 4,250 | -4.5% | 0.07% | -9.1% |
| Q1 2017 | $381,000 | +10.1% | 4,450 | 0.0% | 0.08% | +10.0% |
| Q4 2016 | $346,000 | -0.9% | 4,450 | 0.0% | 0.07% | -1.4% |
| Q3 2016 | $349,000 | -21.4% | 4,450 | +1.1% | 0.07% | -22.8% |
| Q2 2016 | $444,000 | +0.7% | 4,400 | -5.4% | 0.09% | -1.1% |
| Q1 2016 | $441,000 | +2.1% | 4,650 | 0.0% | 0.09% | -2.1% |
| Q4 2015 | $432,000 | +9.1% | 4,650 | 0.0% | 0.10% | +5.6% |
| Q3 2015 | $396,000 | -0.5% | 4,650 | 0.0% | 0.09% | +20.0% |
| Q2 2015 | $398,000 | +0.8% | 4,650 | 0.0% | 0.08% | +2.7% |
| Q1 2015 | $395,000 | -1.0% | 4,650 | 0.0% | 0.07% | -1.4% |
| Q4 2014 | $399,000 | +25.1% | 4,650 | +10.7% | 0.07% | +21.3% |
| Q3 2014 | $319,000 | -5.1% | 4,200 | -1.7% | 0.06% | +1.7% |
| Q2 2014 | $336,000 | +5.0% | 4,273 | 0.0% | 0.06% | 0.0% |
| Q1 2014 | $320,000 | -3.0% | 4,273 | 0.0% | 0.06% | 0.0% |
| Q4 2013 | $330,000 | +11.5% | 4,273 | 0.0% | 0.06% | +1.7% |
| Q3 2013 | $296,000 | +9.6% | 4,273 | 0.0% | 0.06% | +7.3% |
| Q2 2013 | $270,000 | – | 4,273 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |